X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9295) 9295
Publication (1514) 1514
Book Review (113) 113
Book Chapter (88) 88
Dissertation (28) 28
Conference Proceeding (21) 21
Magazine Article (11) 11
Newspaper Article (10) 10
Trade Publication Article (6) 6
Data Set (2) 2
Book / eBook (1) 1
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (5026) 5026
pd-1 (3951) 3951
immunotherapy (3941) 3941
humans (3640) 3640
oncology (3423) 3423
cancer (2883) 2883
immunology (2469) 2469
pd-1 protein (2123) 2123
lymphocytes (1935) 1935
melanoma (1739) 1739
tumors (1739) 1739
female (1654) 1654
nivolumab (1616) 1616
animals (1582) 1582
lymphocytes t (1562) 1562
pd-1 blockade (1559) 1559
expression (1544) 1544
apoptosis (1463) 1463
t cells (1447) 1447
male (1431) 1431
pd-l1 (1363) 1363
immune checkpoint (1247) 1247
pembrolizumab (1125) 1125
mice (1121) 1121
patients (1120) 1120
middle aged (1104) 1104
care and treatment (1065) 1065
pd-l1 protein (1065) 1065
chemotherapy (1064) 1064
ipilimumab (1024) 1024
metastasis (928) 928
t-cells (912) 912
blockade (907) 907
article (905) 905
adult (878) 878
aged (876) 876
research (876) 876
ligands (872) 872
antigens (861) 861
survival (806) 806
safety (791) 791
therapy (786) 786
ctla-4 (784) 784
lung cancer (767) 767
immune system (765) 765
cell death (764) 764
cancer therapies (726) 726
analysis (720) 720
immune response (718) 718
activation (709) 709
health aspects (703) 703
cd8 antigen (692) 692
cytotoxicity (687) 687
dendritic cells (681) 681
programmed cell death 1 receptor - antagonists & inhibitors (666) 666
cell biology (663) 663
open-label (661) 661
anti-pd-1 (658) 658
gene expression (658) 658
clinical trials (655) 655
metastases (628) 628
programmed cell death 1 receptor - immunology (619) 619
biomarkers (616) 616
prognosis (616) 616
medicine, research & experimental (613) 613
immunity (611) 611
programmed cell death 1 receptor - metabolism (598) 598
responses (595) 595
flow cytometry (590) 590
metastatic melanoma (589) 589
antibodies (586) 586
immunotherapy - methods (583) 583
cd8-positive t-lymphocytes - immunology (581) 581
cytokines (561) 561
mutation (546) 546
medical research (542) 542
review (539) 539
antibodies, monoclonal - therapeutic use (534) 534
t-lymphocytes - immunology (528) 528
t cell receptors (520) 520
multidisciplinary sciences (517) 517
immunohistochemistry (513) 513
tumor-infiltrating lymphocytes (508) 508
cell lung-cancer (487) 487
medicine & public health (486) 486
proteins (474) 474
medicine (463) 463
medical prognosis (461) 461
regulatory t-cells (461) 461
exhaustion (459) 459
neoplasms - immunology (459) 459
b7-h1 antigen - metabolism (458) 458
cd4 antigen (458) 458
genetic aspects (454) 454
mice, inbred c57bl (449) 449
pd-1 expression (445) 445
antibody (441) 441
treatment outcome (440) 440
inflammation (436) 436
abridged index medicus (432) 432
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9102) 9102
French (76) 76
German (76) 76
Chinese (46) 46
Japanese (24) 24
Korean (19) 19
Russian (15) 15
Polish (11) 11
Spanish (9) 9
Czech (5) 5
Hungarian (3) 3
Dutch (2) 2
Slovenian (2) 2
Persian (1) 1
Portuguese (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Science Signaling, ISSN 1945-0877, 12/2018, Volume 11, Issue 560, p. eaaw3120
Loss of an E3 ubiquitin ligase that targets PD-1 for degradation leads to inefficient antitumor responses by T cells. 
PD-1 protein
Journal Article
Journal Article
Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 12/2017, Volume 15, Issue 12, p. 1237
Journal Article
Nature medicine, ISSN 1078-8956, 04/2019, Volume 25, Issue 6, pp. 1022 - 1022
In the version of this article originally published, the graph in Extended Data Fig. 2c was a duplication of Extended Data Fig. 2b. The correct version of... 
Immunotherapy | PD-1 protein | Glioblastoma
Journal Article
Immunological Reviews, ISSN 0105-2896, 07/2019, Volume 290, Issue 1, pp. 4 - 5
Journal Article
International Journal of Dermatology, ISSN 0011-9059, 06/2019, Volume 58, Issue 6, pp. 736 - 738
Journal Article
European Journal of Cancer, ISSN 0959-8049, 12/2017, Volume 87, pp. 216 - 218
Journal Article
Science Signaling, ISSN 1945-0877, 09/2018, Volume 11, Issue 546, p. eaav2683
Signaling by the glucocorticoid receptor in NK cells induces expression of the checkpoint inhibitor PD-1 to prevent immunopathology. 
Glucocorticoids | PD-1 protein
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 05/2019, Volume 62, Issue 9, pp. 4703 - 4715
Inhibition of the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction using small-molecule inhibitors is an emerging... 
RECEPTOR | CHEMISTRY, MEDICINAL | PD-1 | PD-1/PD-L1 | T-CELLS
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 09/2018, Volume 24, Issue 17, pp. 4059 - 4061
Patients with glioblastoma (GBM) exhibit a complex state of immune dysfunction involving multiple mechanisms of local, regional, and systemic immunosuppression... 
GLIOMAS | THERAPY | ANTI-PD-1 | ONCOLOGY | CANCER | PD-1 BLOCKADE
Journal Article
Cancer, ISSN 0008-543X, 09/2017, Volume 123, Issue 17, pp. 3285 - 3290
BACKGROUND Immunotherapy has changed the therapeutic landscape in oncology. Advanced uterine leiomyosarcoma (ULMS) remains an incurable disease in most cases,... 
uterine leiomyosarcoma | sarcoma | nivolumab | immunotherapy | anti–programmed‐death 1 (PD‐1) | anti–programmed-death 1 (PD-1) | CELLS | EFFICACY | SAFETY | PD-L1 EXPRESSION | DOCETAXEL | PEMBROLIZUMAB | anti-programmed-death 1 (PD-1) | ONCOLOGY | SARCOMAS | BLOCKADE | IPILIMUMAB | Prognosis | Age Factors | Uterine Neoplasms - pathology | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Dose-Response Relationship, Drug | Neoplasm Invasiveness - pathology | Uterine Neoplasms - mortality | Adult | Female | Retrospective Studies | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Leiomyosarcoma - pathology | Kaplan-Meier Estimate | Treatment Outcome | Disease-Free Survival | Survival Analysis | Uterine Neoplasms - drug therapy | Leiomyosarcoma - mortality | Leiomyosarcoma - drug therapy | Aged | Infusions, Intravenous | Neoplasm Staging | Cohort Studies | Usage | Uterus | Immunotherapy | Leiomyosarcoma | Research | Gene expression | Drug therapy | Health aspects | Health care | Intravenous administration | PD-1 protein | Toxicity | Statistical methods | Modulators | Confidence intervals | Bioindicators | Toxic diseases | Immune system | Statistical analysis | Sarcoma | Immunomodulation | Tumor cells | Phenotypic variations | Patients | Survival | Population (statistical) | Immune checkpoint | PD-L1 protein | Phenotyping | Biomarkers | Cancer | Index Medicus | Abridged Index Medicus | programmed-death 1 (PD-1) | anti
Journal Article